Genentech and Regeneron win Thomson Reuters Allicense Awards for Top BioPharma Deals of the Year
June 25, 2015
Celgene & Juno Therapeutics announce landmark deal for CAR-T Cancer Therapies
July 1, 2015
Thermo Fisher Scientific have signed a definitive agreement to acquire Alfa Aesar, a leading global manufacturer of research chemicals, for £256 million (approximately $405 million USD) in cash.
Alfa Aesar’s parent company, Johnson Matthey, is an advanced materials company with expertise in the development of products and services for all technology-based industries. Based in Heysham, U.K., Alfa Aesar has 480 employees and operates in key research hubs in the United States, Germany, China, South Korea and India. The business generated sales of approximately £78 million (or $125 million) in 2014.
“The acquisition of Alfa Aesar enhances our existing portfolio of chemicals, solvents and reagents to support virtually every laboratory application – from research, to drug discovery and development, to production,” said Marc N. Casper, president and chief executive officer of Thermo Fisher Scientific. “In addition, customers will benefit from greater access to these products through our extensive global commercial reach.”
The transaction, which is expected to be completed by the end of 2015, is subject to customary closing conditions, including regulatory approvals. Alfa Aesar will be integrated into Thermo Fisher’s Laboratory Products and Services Segment.
Read more about the acquisition here.
Follow Evolution Global Talent Attraction on Twitter, Facebook and LinkedIN to keep up-to-date with news and trends from the biotechnology, biosciences, medical device, IT and Intellectual Property industries.
